CD19 and Thrombocytopenia: Following CD19 CAR-T therapy, hematologic toxicities were the most common grade ≥ 3 AEs, including lymphopenia (100%), neutropenia (91.3%), anemia (52.2%), and thrombocytopenia (52.2%) (Fig. S1A).